Eyelash Lengthening Consultation
Luxe lashes may be in reach with LATISSE® (bimatoprost ophthalmic solution) 0.03%
Learn how to prepare for your visit, how to get the most out of it and about any care restrictions here.
If your lashes are thinning as you get older, come to MinuteClinic® for a consultation. We can provide an assessment, and if it's right for you, we can prescribe LATISSE®, an at-home treatment that can give you longer, darker and thicker lashes with full results expected in just 16 weeks.
What to know before your visit
Our practitioners provide this service to patients 18 years or older.
Insurance is not accepted for this service and payment is due at time of visit.
Patients with the following are not eligible for this service at MinuteClinic:
- Currently taking medicine to treat eye pressure including glaucoma
- Had eye surgery or Lasik® in the past year
- Have eye surgery or Lasik® planned in the next three months
- Have an active infection or recent injury to one or both eyes
- Have a lens implant or lens removed from one or both eyes
- Have eyelash loss as a result of chemotherapy
This service is not available to pregnant women or women who are breastfeeding.
Important safety information about LATISSE®
If you use/used prescription products for eye pressure problems, use LATISSE® under doctor care. LATISSE® may cause increased brown pigmentation of the colored part of the eye which is likely permanent. Eyelid skin darkening may occur and may be reversible. Only apply at the base of upper lashes. DO NOT APPLY to lower lid. Hair may grow on skin that LATISSE® frequently touches. If you have eye problems/surgery, consult your doctor about use of LATISSE®. Common side effects are itchy and red eyes. If discontinued, lashes gradually return to previous appearance.
Indication: LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.
Download PDF for full LATISSE® prescribing information.
Warnings and precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution (LUMIGAN®) for elevated IOP. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Adverse reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
Postmarketing experience: The following reactions have been identified during postmarketing use of LATISSE® in clinical practice: burning sensation (eyelid), erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus, iris hyperpigmentation, lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region), skin discoloration (periorbital), and vision blurred.
Use in specific populations
Pregnancy category C
Teratogenic effects: In embryo/fetal developmental studies in pregnant mice and rats, abortion was observed at oral doses of bimatoprost which achieved at least 33 or 97 times, respectively, the maximum intended human exposure (based on blood AUC levels after topical ophthalmic administration to the cornea or conjunctival sac).
At doses at least 41 times the maximum intended human exposure, the gestation length was reduced in the dams, the incidence of dead fetuses, late resorptions, peri- and postnatal pup mortality was increased, and pup body weights were reduced.
There are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% administration in pregnant women. Because animal reproductive studies are not always predictive of human response, LATISSE® should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether LATISSE® solution is excreted in human milk, although in animal studies, bimatoprost has been shown to be excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when LATISSE® is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established.
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.
Use with contact lenses
LATISSE® contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.
What to expect at your visit
- Sign in at the electronic kiosk to see a nurse practitioner or physician assistant.* No appointment necessary.
- Your practitioner will review the patient consent form and potential side effects with you to determine if you’re able to safely use LATISSE®, the eyelash lengthening prescription.
- A completed and signed consent is required for the practitioner to be able to write the prescription.
- Your practitioner will perform an eye exam to make sure there are no signs of infection.
- Your practitioner will write the prescription and review the steps to apply the treatment with you.
- At the end of your visit, your practitioner will provide you with a summary, a receipt and educational material.
*MinuteClinic® employs physician assistants in select states. See here for details.